MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Cabaletta Bio ROA Ratio 2011-2026 | CABA
Annual ROA Ratio Cabaletta Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.68 | -45.29 | -36.64 | -29.06 | -11.98 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.98 | -45.29 | -29.93 |
Quarterly ROA Ratio Cabaletta Bio
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -73.71 | -62.77 | -38.1 | -47.59 | -42.1 | -37.25 | -32.66 | -45.13 | -48.1 | -52.91 | -36.51 | -45.94 | -42.9 | -40.66 | -28.89 | -36.2 | -34.09 | -30.78 | -20.95 | -24.23 | -20.2 | -15.47 | -8.16 | -35.3 | -59.16 | -56.78 | -27.14 | -27.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.16 | -73.71 | -38.24 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | $ 20.13 | -2.75 % | $ 2.54 B | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.8 | -4.99 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-26.55 | $ 163.18 | -1.92 % | $ 8.12 B | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.64 | -4.84 % | $ 1.09 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.37 | -4.12 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 23.82 | -0.25 % | $ 2.91 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Corvus Pharmaceuticals
CRVS
|
-59.34 | $ 17.04 | -4.75 % | $ 818 M | USA |
 |
Champions Oncology
CSBR
|
14.53 | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Daré Bioscience
DARE
|
-18.34 | $ 1.59 | -1.27 % | $ 13.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-173.5 | $ 21.94 | -5.66 % | $ 2.13 B | France |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-37.95 | $ 25.4 | -5.44 % | $ 680 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-2.95 | $ 17.58 | -3.14 % | $ 451 M | USA |
 |
Exelixis
EXEL
|
27.51 | $ 40.7 | -0.8 % | $ 11.1 B | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
-59.73 | $ 7.91 | -3.77 % | $ 210 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.85 | $ 14.35 | -0.1 % | $ 4.43 B | USA |
 |
Galectin Therapeutics
GALT
|
-268.92 | $ 2.95 | -3.59 % | $ 184 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 32.63 | -4.28 % | $ 2.69 B |  Belgium |
 |
Codexis
CDXS
|
-43.81 | $ 0.98 | -3.85 % | $ 71.9 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-385.68 | $ 26.25 | -4.16 % | $ 342 M | USA |
|
Galecto
GLTO
|
-100.32 | $ 28.88 | -3.91 % | $ 767 M |  Danmark |
 |
Genmab A/S
GMAB
|
22.5 | $ 27.42 | -7.52 % | $ 17.6 B | Danmark |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Gossamer Bio
GOSS
|
-57.65 | $ 0.44 | 3.03 % | $ 67.2 M | USA |
 |
GeoVax Labs
GOVX
|
-279.72 | $ 1.52 | -2.88 % | $ 2.76 M | USA |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.51 | -6.38 % | $ 6.83 B |  Spain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-82.01 | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Halozyme Therapeutics
HALO
|
12.55 | $ 68.8 | -1.5 % | $ 8.24 B | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-31.82 | $ 28.35 | -2.91 % | $ 1.64 B | USA |
 |
Hoth Therapeutics
HOTH
|
-106.17 | $ 0.98 | -3.92 % | $ 6.25 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |